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ABSTRACT
Biofilms can be found in any environment within proximity to water and are problematic
in an assortment of industries. Numerous efforts have been employed to dislodge biofilms
including bacteriophages (viruses that infect bacteria). Phage remediation is a promising solution
for combatting biofilms that form on catheters in long term use patients. These biofilms often
result in catheter-associated urinary tract infections (CAUTIs) and are the most common type of
healthcare related infection reported. Additionally, they result in longer hospital stays and
increased morbidity. To date, most of the research on the topic focuses on single species
biofilms, despite their rarity in nature. Here we assess the efficacy of five phages and a phage
cocktail to treat both homogeneous as well as heterogeneous, multispecies biofilms. The effects
of phage treatment were assessed looking at both the absorbance and colony counts of the
biofilm as well as the planktonic fraction. Two phages, Greedy and phiKZ, had the greatest
success in lysing bacterial cells and were thus selected for a phage cocktail treatment regimen.
By evaluating the effects on both monoculture and heterogeneous biofilms, phage species can
more accurately be assessed for their potential use in treating CAUTIs.
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CHAPTER ONE
INTRODUCTION
Biofilms
A biofilm is an aggregation of microbes and substrates from the surrounding environment that
are encased in a microbe-produced complex polysaccharide matrix often adhered to a solid
surface (see review Flemming et al. 2016). There are several phases of biofilm formation. First, a
primer film composed of microbial and environmental molecules forms on the surface of the
substrate (Chondki et al. 2011). Hydrophobic interactions either repel or attract microbes to the
surface, in which attracted bacterial cells bind weakly to each other (see review Kaplan 2011).
Next, in the growth phase, irreversible attachment occurs when the weak bonds are reinforced by
stronger bonds to the cell wall or pili (Rosan and Lemont, 2000). In maturity, the initially
attached bacteria attract other bacteria through means such as cell to cell communication through
chemical signals (quorum sensing). This, in conjunction with cell multiplication and the
secretion of polysaccharides (generating the matrix), results in organization of the biofilm and
the shift from an aerobic environment to a facultative anaerobic environment. When the biofilm
reaches a critical mass, the last phase in biofilm development occurs: dispersal; bacteria are
dispersed into the environment to colonize new areas. Figure 1 illustrates this process.
The microbes within a biofilm differ from their counterparts in the liquid surrounding the
biofilm (the planktonic fraction) in many ways. They may develop an altered phenotype,
including different growth rates (see review Flemming et al. 2016) and transcription profiles
1
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(see review Socransky and Haffajee, 2002). Additionally, communities within biofilms often
display increased gene exchange rates and tolerance to antimicrobials (Flemming et al. 2016).
The polysaccharide matrix provides channels useful for nutrient acquisition and chemical
signaling (Flemming et al. 2016). It also provides physical protection of microbes deeper in the
matrix. These altered properties are unique to biofilms and are thus unpredictable by typical
liquid culture based studies (Flemming et al. 2016). These advantageous effects are compounded
in multispecies (heterogeneous) biofilms when compared with single species (homogenous)
biofilms.

Figure 1. Five phases of biofilm development: (1) initial attachment, (2) irreversible attachment,
(3) initial maturation, (4) later maturation, and (5) dispersion.

Studies have shown that multispecies biofilms, in comparison to their single species
counterparts, have increased mass and resistance to antimicrobials (Lee et al. 2014, Burmølle et
al. 2014). Due to the microscopic matrix structure, members of the microbial community within
a biofilm interact both physically and socially. These social interactions may be cooperative. For
example, microbes within biofilms have been observed to share resistance to, e.g.,
antimicrobials, antibiotics, and toxins (Lee et al. 2014, Burmølle et al. 2014, Chandki et al.
2011); often if a member of the biofilm community is resistant to an antibiotic, the entire
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community becomes resistant. Instances of metabolic cooperation (syntrophy) have also been
observed amongst microbes within biofilms (Lee et al. 2014, Ren et al. 2014). Alternatively,
these microbial social interactions may be antagonistic such as producing chemicals toxic to
other microbes and resource composition (Rao et al. 2005).
Biofilms are a key constituent of the microbial world. They are ecologically important
and can be found anywhere within proximity to water. Biofilms found on rocks in streams
provide sustenance to bottom feeders, indicating their essential role in the food web of streams
(see review Battin et al. 2016). They likewise have immediate benefits for human health. For
instance, within the human microbiota, biofilms in the gut play an important role in degradation
of substrates (de Vos 2015). Biofilms also benefit human health through their important role
within the wastewater treatment process. In fact, three types of biofilms, distinguished by their
structure, are typically included within this process: static biofilms, particulate biofilms, and
flocs (see review Nicolella 2000). Research has found that the presence of a biofilm in the
activated sludge stage of water treatment improves processing performance (Gebara 1999). Yet
another industrial use of biofilms includes their potential applications for bioremediation, e.g.
crude oil degradation (Dasgupta et al. 2013). Biofilm reactors have the potential to revolutionize
production of biological materials (e.g. antibiotics) and even electricity (see recent review
Todhanakasem 2016). While a few of the documented beneficial uses of biofilms are listed here,
this is far from a comprehensive list.
Despite the many ecological benefits of biofilms, they can also be detrimental.
Problematic biofilms include, for example, those that form on the bottom on boats or in fuel
tanks, food processing centers, municipal drinking water systems, or sewer systems in large
cities (e.g. Drake et al. 2005, Hvitved-Jacobsen et al. 2013, Douterelo et al. 2016). Biofilms can
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also be detrimental to human health (Macfarlane and Dillon 2007). In cystic fibrosis patients, P.
aeruginosa biofilms form in the lungs and are extremely difficult to treat due to the protective
nature of biofilms (Høiby et al. 2010). Biofilms that form on the teeth of animals and humans
(plaque) cause periodontal disease (Chandki et al. 2011). Infection and biofilm formation within
the human body can have severe and even lethal effects and is thus an important area of research
within the biomedical community.
Phage Therapy
Given the many detrimental effects biofilms have on human health, strategies for combating their
formation as well as their destruction are of critical importance. Biofilm treatment using
bacteriophage (phage therapy) is a particularly promising approach. Bacteriophages or phages
are viruses that infect bacteria; they are nature’s biological weapon against bacteria. Here we will
briefly review the aspects of bacteriophage biology of relevance to our study and refer the reader
to the many excellent available reviews, including Clokie et al. (2011), for further details about
phages. When lytic phages encounter a bacterial cell host, they inject their DNA or RNA
genome. Once inside the host, the phage replicate and eventually trigger the bacterial host cell to
“burst.” Phage progeny are released with this burst to hunt new hosts (bacteria). This process,
called lysis, has been found to play a significant role in bacterial death in several ecosystems
(e.g. Berdjeb et al. 2011).
Bacteriophage remediation is also a promising approach as phages can be grown within
the laboratory at minimal expense. In fact, some phages produce specific enzymes for the
degradation of the polysaccharide matrix that is central to the stability of biofilms (Harper et al.
2014). Moreover, phages typically have a narrow host range; they are often only capable of
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successfully infecting and lysing a single bacterial species or strain. Thus, phages can be used to
specifically target a bacterial infection with high efficacy (Koskella and Meaden 2013).
Phage therapy, however, does raise reasonable concerns. For instance, when phage lyse
(kill) bacteria, toxins may be released into the body and/or encoded by the phage itself (LocCarrillo and Abedon 2011). Lysis also can lead to the rapid release of lipopolysaccharides from
the bacterial cell wall that, when at high concentrations, can lead to cytokine cascades (Nilsson
2014). Furthermore, phage treatment of internal organs, many of which are not natural
environments for phages, has been shown to activate an immune response (Nilsson 2014). In
targeting one biofilm, it is important to remember that the human body is composed of many
beneficial bacteria that support health (see review Lloyd-Price et al. 2016). Thus, phage therapy
may lead to subsequent infections or dysbiosis.
In addition to these concerns, there are several challenges for phage therapy. First and
foremost is the ability to administer phage treatment. As phage treatment would be most
effective if introduced in close proximity to the bacterial infection, this is a hurdle when the area
or organ being treated cannot be easily accessed. It is for this reason that phage therapy has been
most successful for “easy-to-reach” infections, e.g. acne (Jonńczyk-Matysiak et al. 2017). The
greatest obstacle facing the wide-spread adoption of phage therapy, however, is evolution itself.
While phages can infect and kill bacteria, they are in a constant arms race with bacteria, which
are continually evolving resistance to infection from phages (Dennehy 2012). This race is
expedited by the short generation times of bacteria and phage.
To combat this problem, research has focused on phage cocktails (combining multiple
phages for treatment), and using phage treatment in combination with antibiotics or chemicals.
One study found a cocktail of seven phages to be effective at inhibiting Staphylococcus aureus
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biofilms (Kelly et al. 2012). The phage ΦPan70 was successful at treating Pseudomonas
aeruginosa biofilms in mice with an animal survival of 80-100% (Holguin et al. 2015). Quorum
sensing enzymes secreted by a modified T7 phage inhibited biofilm formation in heterotrophic
Escherichia coli and P. aeruginosa biofilms (Pei and Lamas-Samanamud 2014). Two phages
were used to reduce Campylobacter jejuni biofilms on glass slides; C. jejuni biofilms are
problematic in the digestive tract and water pipes (Siringan et al. 2011). In the work of Chaundry
et al. (2017), P. aeruginosa biofilms were more effectively treated with a combination of phage
and antibiotics than either treatment alone. These are but a few studies exploring phage
remediation of biofilms. The rise in antibiotic-resistant bacteria has impelled research efforts to
identify phage species capable of combating a variety of common infections.
Catheter-Associated Urinary Tract Infections
Biofilms that form in long-term use urinary catheters are particularly problematic. These
biofilms, if left untreated, can lead to catheter-associated urinary tract infections (CAUTIs).
According to the Center for Disease Control and Prevention (CDC), CAUTIs are the number one
urinary tract infection (UTI) contracted in the hospital (CDC 2017). Furthermore, per a March
2016 CDC press release, one in ten CAUTIs are caused by urgent or serious antibiotic-resistant
bacteria (CDC 2016). For this reason, much research has gone into CAUTI treatment and
reducing the occurrence of CAUTIs (see reviews Siddiq and Darouiche 2012, Tenke et al. 2017).
Chemical treatment of catheters with Triclosan (Jones et al. 2006), EDTA (Percival et al. 2009)
or Fluorofamide (Morris and Stickler 1998) has yet to show a sufficient reduction in CAUTI
cases. Investigations into other materials (glass, polystyrene, and plastics) used in catheter
construction have unfortunately not produced a reduced incidence of CAUTIs (see review Tenke
et al. 2017). Catheters fitted with silver electrodes were successful in decreasing the rate of
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biofilm formation when electric currents were applied (Chakravarti et al. 2005). This study and a
subsequent study (Voegele et al. 2015), however, have been limited to in vitro models. Of
particular recent interest, the application of phages has also been explored for thwarting catheterassociated biofilm formation and CAUTIs (see review Siddiq and Darouiche 2012) and will be
discussed in greater depth in a subsequent subsection of this chapter.
While several bacteria have been associated with CAUTIs, the most prevalent is Proteus
mirabilis. P. mirabilis is a quorum sensing bacteria found in soil, water, and the digestive tracts
of multiple animals. Quorum sensing (QS) bacteria send out chemical signals as a means of
communicating with other members of its community, an ability which can be quite
advantageous to the bacterium, particularly during biofilm formation. With P. mirabilis’ capacity
for both swarming and swimming motility (Williams et al. 1978), coordination between the two
processes is of particular interest (Rossman et al. 2015). Research has found that P. mirabilis can
detect cues in the surrounding environment triggering its switch from swimming to swarming or
vice versa (Armbruster et al. 2013). Swarming cues, including L-arginine, DL-histidine, Lglutamine, malate, and DL-ornithine, are all present in normal human urine and can thus initiate
the establishment of biofilms within catheters (Armbruster et al. 2013). Furthermore, P. mirabilis
is also able to form crystalline biofilms as a result of urease activity, which in humans can result
in the occurrence of CAUTIs (Mobley and Warren 1987, Stickler et al. 1993, Holling et al.
2014).
Other common species associated with CAUTIs include Pseudomonas aeruginosa,
Escherichia coli, Klebsiella pneumoniae, Serratia marcesens, and Morganella morganii (Gravey
et al. 2017). Herein we will focus on just two of these taxa as they are amongst the best studied
in microbiology: P. aeruginosa and E. coli. Like P. mirabilis, P. aeruginosa is a QS bacterium.
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It is commonly found in the skin flora, soil, and water. P. aeruginosa is also an opportunistic
human pathogen associated with pulmonary infections, particularly in cystic fibrosis patients, as
well as infections of burn wounds and chronic wounds (Mulcahy et al. 2014). P. aeruginosa
utilizes its unipolar flagella for swarming and swimming motility. Additionally, P. aeruginosa
siderophore activity could have an important effect on community structure and dynamics within
a biofilm (Cornelis and Dingemans 2013). The second bacterium of interest is E. coli, which can
also be a constituent of catheter biofilms and is the most common cause of UTIs (Hooton et al.
2010). E. coli, while non-quorum sensing, utilizes its type I pili for biofilm initial attachment and
potentially the spread of biofilm growth across a solid surface (Pratt and Kolter 1998). Efficient
biofilm formation has been observed for E. coli species in environments replicating the bladder
and catheters (Azevedo et al. 2014).
Bacteriophages of the Urinary Microbiota
In many areas of the human microbiome, most notably the gut (Manrique et al. 2017), overall
microbial community structure is largely dictated by phages. Changes in the “native” human
virome (viral community - both eukaryotic viruses that infect human cells and phages) have been
associated with diseases and perturbations, e.g. inflammatory bowel (Norman et al. 2015,
Manrique et al. 2016), periodontal disease (Ly et al. 2014), and the spread of antibiotic
resistance (Modi et al. 2013), among others. Phages are also present within the microbiota of the
bladder. Sequencing of voided urine from individuals with and without a UTI revealed the
urinary virome (Santiago-Rodriguez et al. 2015). Similar to that observed within the gut
microbiota, the urinary virome study found that phages vastly outnumber eukaryotic viruses in
the urinary virome (Santiago-Rodriguez et al. 2015). In addition to phage detection via largescale whole genome sequencing efforts (Rani et al. 2016, Santiago-Rodriguez et al. 2015), phage
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species have been isolated directly from the urinary microbiota and characterized in the lab,
including seven isolated in the Putonti lab (Malki et al. 2016).
In contrast with other areas of the human microbiome, the bacteria and phages present
within the bladder are just now beginning to be explored. It was long believed that the urinary
tract of healthy (asymptomatic) individuals was sterile. It was for this reason that during the
Human Microbiome Project, which cataloged the bacterial species present within the human
body, the bladder was omitted. This longstanding belief, however, was overturned when the
bladder was found to include a variety of bacterial species (Wolfe et al. 2012). Prior work in the
Putonti lab found that latent (dormant) phages are prevalent within bacterial species from the
female bladder. Analysis of the genomes of over 200 bacteria isolated from the female urinary
microbiota has found >80% harbor phage sequences (Miller-Ensminger et al., unpublished). This
initial work and focused studies on bacterial strains from the bladder (Malki et al. 2015) suggests
that phages are highly prevalent within the urinary microbiota. Details regarding phage host
range and the role that phages play in shaping the bacterial populations within the bladder,
however, have yet to be determined.
Phage Therapy for Catheter-Associated Biofilms
The use of phage treatment to inhibit and reduce biofilm formation began in 2006 when Curtin
and Donlan showed that Bacteriophage 456 could be used to treat catheter-associated
Staphylococcus epidermis biofilms (Curtin and Donlan 2006). Several phages were found to be
90% effective in disrupting the formation of homogenous E. coli and P. mirabilis biofilms in
comparison to untreated controls (Carson et al. 2010). With the development of a catheter model
system, phage M4 and four other phages were tested to treat P. aeruginosa biofilms (Fu et al.
2010). While a P. aeruginosa colony resistant to all five phages was uncovered, it had a reduced
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growth rate (Fu et al. 2010). The bacteriophage T7 was also found to be successful in inhibiting
biofilm formation of more complex communities including both E. coli and P. aeruginosa (Pei
and Lamas-Samanamud 2014). Similarly, phage capable of inhibiting biofilm formation for other
pairs of CAUTI-associated bacteria have been studied (Lehman and Donlan 2015).
One avenue of phage therapy specific to catheter-associated biofilm formation is the
potential to pretreat catheters with specific phage(s). For instance, catheters pretreated with a
phage cocktail showed inhibition of P. aeruginosa biofilm growth; this success, however, was
short-lived as P. aeruginosa biofilm growth resumed at 24 hrs post-treatment (Fu et al. 2010).
Other studies have been more successful. For example, two phages were used to treat catheters
and showed significant reduction of P. mirabilis biofilms for up to 168 hrs after treatment (Melo
et al. 2016). In another study, catheters were pretreated with a “benign” strain of E. coli and
phage to successfully inhibit biofilm formation (Liao et al. 2012).
Prior research in phage therapy for catheter-associated biofilms has routinely found that
the timing of phage treatment is vital to its effectiveness. While pretreatment of catheters with
phage can inhibit biofilm formation, phage treatment of established biofilms has been less
effective. While it may delay biofilm growth, as one study found, catheter blockage is often
inevitable (Nzakizwanayo et al. 2015). Further testing of phages is thus needed to determine the
viability of a phage therapy solution for the prevention and treatment of biofilms within catheters
and resulting CAUTIs.
Specific Aims
While prior research exploring phage therapy for catheter-associated biofilms has largely
focused on homogenous biofilms in the laboratory, biofilms from patients with CAUTIs can be
significantly more complex, i.e. include multiple species (Saint and Chenoweth 2003). Thus,
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phage therapies capable of disturbing complex biofilm communities, have a greater potential to
reduce infection rates in patients. My study explores the efficacy of phage treatment on the
biofilms of three bacteria commonly associated with catheter biofilms (P. mirabilis, E. coli, and
P. aeruginosa), investigating both homogeneous (monoculture) biofilms as well as heterogenous
(multispecies) biofilms. To the best of our knowledge, this is the first study considering phage
therapy for three species biofilms of catheter-associated bacteria.
This work is aimed at answer three questions. First, which phage(s) reduce biofilms?
Second, how does phage treatment affect bacterial growth and community dynamics? Third, how
does phage treatment affect bacterial phage resistance?

CHAPTER TWO
METHODS
Bacteria and Bacteriophage Strains
Three bacterial species were used in this study: Proteus mirabilis CDC PR 14, Pseudomonas
aeruginosa 1C, and Escherichia coli C. P. mirabilis and P. aeruginosa were obtained from the
American Type Culture Collection, strains ATCC 29906 and ATCC 15692, respectively. E. coli
C was obtained from Dr. Christina Burch (University of North Carolina Chapel-Hill). Each
bacterium was propagated in liquid culture using LB (10.0 g/L tryptone, 5.0 g/L yeast, 10.0 g/L
NaCl). Liquid cultures were grown at 37°C in a shaking (200 rpm) incubator.
Bacteriophages used in this study are listed in Table 1. Bacteriophages Habibi, Greedy,
and Lust were isolated by our lab and have been described previously in the literature (Malki et
al. 2015; Malki et al. 2016). Bacteriophage phiKZ was obtained from the Felix d’Herelle
Reference Center for Bacterial Viruses (Quebec, Canada), strain designation HER153. DMS3
was obtained from the O’Toole Lab (Dartmouth University). As shown in Table 1, the phages
utilized in this study vary in their natural habitat as well as host range. Habibi and phiKZ both
belong to the family of viruses Myoviridae. This family of viruses are characterized by their
contractile tail sheath (Maniloff and Ackermann, 1998). PhiKZ is one of the largest documented
members of this family (Herdtvelt et al. 2005), as most Myovirdae phages have genome sizes on
par with that of Habibi. Greedy, Lust, and DMS3 are Siphoviridae phages. In contrast to
Myoviridae, Siphoviridae viruses have long, noncontractile tails (Maniloff and Ackermann,
12
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1998). The phages Greedy and Lust were both isolated from the urinary microbiota (Malki et al.
2016) and thus have particular relevance to the study conducted here. Figure 2 shows electron
microscope images for the five phage species.
Phage
Origin
Host
Family
Genome Size
Habibi Lake Michigan E. coli & P. aeruginosa Myoviridae
65.73 kbp
Greedy Bladder Isolate
E. coli
Siphoviridae
60.04 kbp
Lust
Bladder Isolate
E. coli
Siphoviridae
41.94 kbp
phiKZ
Sewage
P. aeruginosa
Myoviridae
280.30 kbp
DMS3 Clinical isolate
P. aeruginosa
Siphoviridae
36.42 kbp
Table 1. A summary of information about the five phages used in this study.

GC%
54.9
44.6
54.5
36.8
64.3

Figure 2. Images of the phages used in this study. (A) Habibi (Malki et al. 2015), (B) phiKZ
(Fokine et al. 2007), (C) Greedy (K. Malki, unpublished data), (D) DMS3 (Budzik et al. 2004),
and (E) Lust (K. Malki, unpublished data).
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Growth Curves
Growth curves were conducted to determine the exponential growth phase of the bacteria. This
knowledge is useful in deciding the opportune time to inoculate cultures with phage in isolation
attempts. Furthermore, the growth curve enables us to estimate the number of bacterial colonies
in a culture at a given time point, this is used to ascertain the appropriate phage concentration to
use in treatments. Prior to this study our lab performed growth curves for E. coli and P.
aeruginosa (unpublished data) which were referenced for those cultures.
To generate the growth curve for P. mirabilis, a single colony was used to inoculate a 50
mL flask of LB and glass beads, the culture was then grown for 21 hrs. 100 µl was used to
subculture three flasks containing 300 mL of LB and glass beads. The glass beads were added to
the culture to minimize biofilm formation. Three mL aliquots were taken from each replicate
every 15 mins for that first 90 mins after inoculation. Samples were then taken every half-hour or
hourly for 17.5 hrs post-inoculation. Additional samples were collected at 25 and 33.5 hrs to
capture the stationary phase of growth. In total, 32 samples were collected. From the 3 mL
sample collected, 2 mL was placed immediately on ice until plating/storage and 1 mL was
assayed via the spectrophotometer. Readings were taken at 660 nm and 750 nm. For plating, 8fold serial dilutions were performed; 100 µl of the aliquot was serially diluted into 1 mL of LB
eight times, thus reducing the number of bacterial cells with each dilution by 1:10. For each
dilution, 100 µl was spread on an LB plate using a sterile spreader. Plates were subsequently
placed in a non-shaking 37°C incubator overnight. Colonies were counted the following day or
replated if necessary. Figure 3 shows the growth curve produced, the first growth curve of P.
mirabilis CDC PR 14 to our knowledge.
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Figure 3. P. mirabilis growth curve. Standard deviation error bars are shown for the three
replicates.

Biofilm Selection Experiment
A single colony of P. mirabilis, E. coli, or P. aeruginosa was added to 20 mL of LB within a 50
mL capped centrifuge tube containing a sterile microscope glass slide. After overnight growth at
37°C in a 200 rpm shaking incubator, a sterile loop was used to sample from the center of the
biofilm formed on the slide. This sample was then used to inoculate 20 mL of LB, again within a
50 mL capped centrifuge tube containing a microscope glass slide. Samples from these biofilms
were also streaked on an LB plate or low-salt LB (LSLB) (0.5 NaCl g/L) plate (LSLB plates
reduce P. mirabilis swarming), to ensure contamination had not occurred. The following
protocol was conducted for up to 19 passages. By selecting only bacteria which successfully
biofilmed to propagate subsequent populations, this experimental protocol selected for strains
that were efficient in forming biofilms. The passages were continued until a visible biofilm was
established and could be reproduced from a single colony selected from the streaked bacterium.
Images of representative biofilms are shown in Figure 4.
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Figure 4. Biofilm formation on glass slides. Images are from left to right P. aeruginosa, P.
mirabilis and E. coli.

Phage Growth and Titration
Each phage was plated from our lab’s freezer stock and validated for uniform plaque
morphology. A single plaque was harvested such that all subsequent work was derived from a
single genotype. To harvest phage, a 1000 µl pipette tip was used to puncture the agar around the
plaque and then transferred to a microcentrifuge tube containing 1000 µl of LB. The tubes were
then vortexed for 10 mins using the Disruptor Genie vortex (Scientific Industries). Next, tubes
were centrifuged at 10,000xg for 1 min and the lysate was transferred to a fresh microcentrifuge
tube. Samples were chloroformed (1-2% by volume) and tubes were vortexed for 10 secs. Prior
to transferring the lysate, samples were centrifuged again as described previously. Lysates were
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then spotted on their respective bacterial hosts using the double layer agar method, in which a
1.7% agar LB plate was overlaid by 3 mL of 0.7% agar LB (LBSA) mixed with 1 mL of
bacterial culture. These plates were then grown overnight at 37°C in a non-shaking incubator.
Phage plaques were scraped off of the agar with a sterilized scoopula, transferred to a
microcentrifuge tube containing 1000 µl of LB, chloroformed, vortexed and centrifuged.
An 8-fold dilution of the lysate was then performed and plated to determine phage titer.
For dilutions: 100 µl of phage harvest was aliquoted into 1 mL of LB. A stepwise dilution was
conducted, reducing the phage population with each transfer by 1:10. Lust, Greedy, phiKZ, and
DMS3 were grown, harvested, and plated until plaques were visible at 10-8. The titers of Lust
and Greedy were increased through growth on their host E. coli while the titers of phiKZ and
DMS3 were increased through growth on their host P. aeruginosa. Habibi was propagated until
plaques were visible at 10-7 dilution on P. aeruginosa and 10-5 dilution on E. coli. In order to
retain Habibi’s ability to successfully lyse both P. aeruginosa and E. coli, culture in both
bacterial species was necessary. Titers for all five phages were confirmed via a pour plate in
triplicate in which two consecutive dilutions were plated. Pour plates were produced as follows:
100 µl of the appropriate dilution was added to 1 mL of the phages host and placed on the
benchtop for 10 mins before adding 3 mL of 50°C LBSA. This mixture was then poured over an
1.7% agar LB plate. After setting, plates were placed in a 37°C non-shaking incubator and
allowed to grow overnight. Plaques were then counted.
Biofilm Experimental Design
The experimental design is depicted in Figure 5. Briefly, 20 mL of LB was added to a 50 mL
capped centrifuge tube in addition to a sterile microscope glass slide. Glass slides were sterilized
by submerging them in 70% EtOH after which they were placed in a sterile hood overnight for
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EtOH evaporation. Each tube was inoculated with a single colony of the bacterial species. (When
more than one bacterial species was used to form a biofilm, the culture was inoculated
simultaneously with a single colony from each species.) The tube was incubated at 37°C,
shaking at 200 rpm. After a 24-hr incubation, the glass slide was removed with sterile forceps.
Excess liquid was removed from the bottom of the slides with a Kimwipe, and the slides were
placed into new 50 mL tubes with 20 mL of fresh LB. Each slide was then treated with phage (or
no phage in the case of the control). The 24 hr time point was chosen because after a day
organization of bacterial species and the matrix has taken place and is truly considered a biofilm
(Chandki et al. 2011). Following treatment, tubes were returned to the incubator and allowed to
grow for an additional 24 hrs at 37°C, shaking at 200 rpm. Next the glass slides and a portion of
the planktonic fraction were removed for further analysis.

Figure 5. A visualization of the experimental design including biofilm growth and treatment. (1)
Empty sterile 50 mL centrifuge tube. (2) 20 mL of LB and (3) a sterile glass slide was placed in
the tube. A single bacterial colony per species is added and allowed to grow for 24 hrs resulting
in biofilm formation (4). (5) The glass slide was removed and placed into a centrifuge tube
containing fresh LB. Treatment was then applied to the slide and placed in the incubator for an
additional 24 hours. (6) The slide and planktonic fraction from the tube is separated for
subsequent analyses.
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For Greedy, Lust, phiKZ, and DMS3 treatments, 100 µl of phage (~10 phage/µl) was
added to 200 µl of phosphate buffered saline (PBS) (8 g/L NaCl, 0. 2g/L KCl, 1.44 g/L
Na2HPO4, and 0.24 g/L KH2PO4, adjusted to pH=7). For Habibi treatments, 100 µl of phage
(~105 phage/µl in P. aeruginosa and ~103 phage/µl in E. coli) was added to 200 µl of PBS. The
decreased titer of Habibi was used to remain consistent in treatment volumes and because of
Habibi’s unique ability to infect and lyse two potential members of the biofilm.
All combinations of the three bacteria received each individual phage treatment in
addition to no treatment (PBS) in triplicate. E. coli, P. aeruginosa, and E. coli + P. aeruginosa
(EP) biofilms also received a phage cocktail treatment consisting of phiKZ and Greedy. The
cocktail treatments included 50 µl of each phage (~106 phage/µl) in 200 µl of PBS. Alongside
each set of biofilm samples, a forth biofilm was also grown to check for contamination of slides,
LB, and/or PBS. Serving as a negative control, these samples were not inoculated with any
bacterial species and were treated with 300 µl PBS at the 24 hr mark. Figure 6 lists the
treatments conducted.
Mass
Biofilm formation and effects of phage treatment were evaluated based upon the mass of the
biofilm. Dry weights of 1.5 mL microcentrifuge tubes were recorded using a scale. One mL of
sterile LB broth was added and weight was again recorded. For biofilms: glass slides were
removed from 50 mL centrifuge tubes using sterile forceps, the bottom of the slide was touched a
Kimwipe to remove excess liquid, and the established biofilm was scraped off of both sides of
the slide using inoculating loops and placed into the LB containing microcentrifuge tubes. All
tubes were subsequently vortexed and weighed. For the planktonic fraction: tubes containing LB
were centrifuged and LB was removed and replaced by 1 mL of the planktonic fraction from
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biofilm samples. Dry weights and LB weights were subtracted from final weights to obtain the
mass of the biofilm and planktonic fraction.

Figure 6. An image depicting biofilms generated and the treatments which were applied to them.
The phage cartoon indicates that phage treatment was applied and a water droplet represents PBS
treatment (control). All treatments for biofilms were conducted in triplicate. Biofilm cultures are
abbreviated according to the bacteria used in the culture as follows. E=E. coli; P=P. aeruginosa;
M=P. mirabilis; EP=E. coli and P. aeruginosa; EM=E. coli and P. mirabilis; PM=P. aeruginosa
and P. mirabilis; and EPM=E. coli, P. aeruginosa, and P. mirabilis. Biofilms and the planktonic
fraction were analyzed via absorbance, colony counting and host range.
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Spectrometry and Colony Counting
All spectrometry readings were done at 660 nm; blanks consisted of 1 mL LB broth. For the
planktonic fraction, 1 mL was removed from the sample following 48 hrs of growth, vortexed for
10 secs, aliquoted into a cuvette, and the absorbance was recorded. Resuspended biofilms from
the mass reading were vortexed for 10 secs, removed from the microcentrifuge tube, and
aliquoted into a cuvette and the absorbance was recorded. After recording the absorbance, each
sample was returned to its original microcentrifuge tube for further analysis. For colony counts,
100 µl of the resuspended biofilm or planktonic fraction was used to perform an 8-fold serial
dilution as described previously. Two dilutions were plated for each sample; 100 µl of the
dilution was aliquoted onto an LB plate or a low-salt LB (LSLB) (0.5 NaCl g/L) plate, spread
using a sterilized spreader, and allowed to dry. The plate was then incubated at 37°C overnight.
Colonies were counted for each plate and recorded. For samples inoculated by more than one
bacteria, counts were determined for each individual species as identified visually via colony
morphology and color. Plates were stored at 4°C.
Bacterial Resistance Assay
LSLB and LB plates were prepared for assessing the phage sensitivity of bacterial isolates from
untreated and treated biofilms; LSLB plates were used to test P. mirabilis isolates and LB plates
were used to test E. coli and P. aeruginosa isolates. Regardless of the bacterial species or phage
being examined, plates were prepared as follows: 50 µl of naïve phage lysate was spread down
the center of the plate and allowed to dry. From the plates produced for colony counting, three
random colonies were picked for each species and streaked across the prepared plate, across the
region containing the phage lysate. The plates were then incubated overnight at 37°C. Figure 7
presents a representation of the results observed. If the bacterial growth was consistent through
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the phage treated portion of the plate, it was considered resistant (Figure 7A). Bacterial growth
that stopped at the beginning of the phage treated portion of the plate was considered sensitive
(Figure 7B). Variation between resistant and sensitive growth was considered partially resistant
(Figure 7C). As a control, an additional colony was streaked through an area of the plate
containing no phage treatment (Figure 7D).

Figure 7. Generalized visualization of method for determining resistance categories: (A)
resistance to phage infection (B) susceptibility, (C) partial resistance, and (D) negative control.
Green lines represent bacterial growth. Phage treatment was applied in the black box containing
A-C. No phage was applied to the black box containing streak (D).

Phage Identification
Phage specific primers were designed using primer3 (Untergasser et al. 2012) for all phages as
well as the documented prophage within the P. aeruginosa strain used in this study. For primer
design, the genomes of each of the five phages were retrieved from NCBI. To determine the
prophage sequence, we used PHASTER (Arndt et al. 2016, Zhou et al. 2011). The primers
designed are listed in Table 2. All primer pairs were checked for self-priming and dimerization
using the ThermoFisher Scientific Multiple Primer Analyzer (ThermoFisher Scientific 2017).
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Additionally, all primer pairs were checked for specific amplification computationally by
querying each sequence via BLASTX against the nr/nt collection, and at the bench via PCR
against DNA from each other phage and each bacterial host.
Phage
Primers
Amplicon Size Targeted Region
Lust
GATGCGCAAGGAGTTAGAGC 873 bp
DNA methylase
(KX534338)
ACGTGACACTCGCTTCACAC
Greedy
TGCTAGTGGCCAGCATAGTG 758 bp
hypothetical
(KX534337)
TTGTAGAAGTGCAGCCGATG
protein
Habibi
ACCGACTCACGACGATGG
904 bp
putative structural
(KT254132)
CGGCAAGGTGTTCGCTTA
protein
DMS3
AACCGAACCTGAAAATGAC
625bp
putative C
(NC_008717)
ATCCAAGTCAGAAAGCTGGT
repressor
phiKZ
CACGCGTGTAATCAAGACC
964 bp
structural head
(NC_004629)
CCTACTCGTTGGCCAAGTC
protein
P. aeruginosa
GTGGAGCCAGAGTTTTACTG 527 bp
annotated
prophage
ATAGCGTAGGGAAAGGAATC
prophage
(NZ_CP017149)
Table 2. Primers used for the amplification of phage species. Accession numbers are listed for the
genome sequences used to design the primers.

The PCR primers designed here were tested against genomic DNA extracted for each of
the phages used in this study and for the P. aeruginosa genome (for the detection of the prophage
sequence). PCR set up was as follows: 25 µl Ready PCR mix 2x (Amresco LLC), 0.5-1 µl
forward primer, 0.5-1 µl reverse primer, 0.5-3 µl template, 20-23.5 µl nuclease free water.
Thermocycler conditions for each phage tested are listed in Table 3. It is worth noting that this
table does not include thermalcycling conditions for the identification of phiKZ. Attempts at
phiKZ-specific PCR were unsuccessful due to insufficient phage concentration. Other phiKZ
primers in our collection were also tested (results not shown) but were not successful in
producing visible amplicons either. To identify phiKZ, plaques were tested against the prophage
primers, in the event of no amplification, phiKZ was assumed.
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Initial
Denature
Denature Annealing Extension
94°C
94°C
55.5°C
72°C
10 mins
30 secs
45 secs
1 min
94°C
94°C
52°C
72°C
15 mins
30 secs
45 secs
45 secs
DMS3
94°C
94°C
54°C
72°C
15 mins
30 secs
45 secs
45 secs
P. aeruginosa
94°C
94°C
55°C
68°C
prophage
10 mins
30 secs
30 secs
30 secs
Table 3. Thermocycler conditions for phage identity testing.
Phage
Greedy and
Lust
Habibi

# cycles
30
45
30
30

Final
extension
72°C
5 mins
72°C
5 mins
72°C
5 minutes
68°C
5 mins

Planktonic and biofilm samples were chloroformed (2% by volume), vortexed for 10
secs, and lysate was separated from the pellet. Subsequently, an 8-fold dilution was performed
using 100 µl of serially diluted lysate. Dilutions were spotted onto naïve lawns of each bacterial
species present in the biofilm. If lysis was observed after overnight growth, pour plates at the
corresponding dilutions were performed. Ten random plaques were harvested from each plate as
previously described (section “Phage Growth and Titration”). Plaque harvests were stored at
4°C.
To identify the phage(s) producing the observed plaques, 50 µl of phage lysate was used
to inoculate 1 mL of a naïve culture of the bacterial host, the bacterium on which the phage was
harvested. Following overnight growth each sample was chloroformed (20 µl), vortexed,
centrifuged (16,100xg rpm for 2 mins) twice, and the lysate was transferred to a sterile
microcentrifuge tube. PCR reactions were immediately performed following the phage-specific
protocol listed in Table 3. For positive controls 1 µl DNA was used. For PCR reactions of the
samples, 3 µl of lysate was used. Amplicons were visualized using a 1.2% agarose gel.
If phage lysate PCR was unsuccessful, 10 µl of the phage lysate was plated using the
double layer agar method previously described. Following overnight growth at 37°C, spots were
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harvested and suspended in 300 µl nuclease-free H2O. This suspension was vortexed for 10
mins, chloroformed (20 µl), vortexed 10 secs, and centrifuged at 16.1 rpm for 2 mins. Each
sample was chloroform treated three times to ensure no viable host cells remained. Lysate was
removed, separated from the pellet, and used as the sample input for PCR. If this PCR was
unsuccessful, lysate was regrown as previously described and phage DNA was extracted using
the UltraClean® Microbial DNA Isolation Kit (Mo Bio Laboratories). The manufacturer’s
protocol was followed with the following exceptions: rather than pelleting down the sample for
bacterial extraction, 300 µl of viral lysate was used with 250 µl of bead solution. Furthermore, a
70°C heat step was added to increase DNA yield.
Phage Host Range Assay
Phage host range was tested in triplicate before experimental treatment. To test, 10 µl of pure
phage cultures were spotted on bacterial lawns, allowed to dry, and incubated overnight at 37°C.
To reduce the risk of contamination, spotting was limited to a single phage per plate. For phages
that were able to infect multiple hosts, dilutions were plated so that individual plaques could be
harvested. Single plaque harvests were subsequently used to confirm that plaques on multiple
species were in fact the same phage. Post experimental host range was recorded using phage
identification results.
Statistical Analysis
Statistical analyses were performed in R (R core Team 2013). Data for each biofilm was
considered separately. For example, data collected for all of the 18 E. coli biofilm absorbance
data points were considered and checked for normality using the shapiro.test function before and
after any necessary transformations. Abnormally distributed data was log transformed, if the
transformation failed to normalize the data a box-cox transformation was performed using the
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bctransform function in the MASS (Venables and Ripley, 2002) package. If normalization was
successful, a one way ANOVA was performed using the aov. function in the Rcmdr package
(Fox and Bouchet-Valat, 2017; Fox 2017; Fox 2005). If the ANOVA resulted in a significant
difference between treatments, a Tukey’s multiple comparison test was performed using the
TukeyHSD function to identify which treatments were significantly different from each other. If
data could not be normalized the Kruskal.test function was used.

CHAPTER THREE
RESULTS AND DISCUSSION
Five phage species were selected for this study and are described in detail in the Methods and
Table 1. Briefly, bacteriophage Greedy and Lust, both isolated from the microbiota of the human
bladder (Malki et al. 2016), can effectively infect and lyse several E. coli strains including E. coli
C. The bacteriophage phiKZ, isolated from sewage (Krylov et al. 1978), and DMS3, induced
from P. aeruginosa clinical isolates (Budzik et al. 2004), are both capable of infecting and lysing
P. aeruginosa including several human pathogenic strains of P. aeruginosa (Mesyanzhinov et al.
2002). The fifth phage selected for this study is bacteriophage Habibi, which was isolated from
Lake Michigan nearshore waters and is capable of infecting both E. coli and P. aeruginosa
strains, amongst other bacterial taxa (Malki et al. 2015). Habibi is considered a broad host range
phage, as it is capable of infecting across genera, while the other four phages used in this study
are narrow host range phage, capable of infecting only strains of the same species.
Thus, our study includes phage species capable of infecting two of the bacterial species
frequently associated with biofilms within catheters and CAUTIs. None of the phages, however,
can infect the CAUTI-associated bacterium P. mirabilis. Although significant efforts were made
to isolate a phage capable of reliably infecting and lysing P. mirabilis, we were unable to isolate
a phage that could work consistently under standard laboratory conditions (results not shown).
Furthermore, our attempt to purchase a P. mirabilis-infecting phage from the Felix d’Herelle
Reference Center for Bacterial Viruses (Quebec, Canada) was also unsuccessful; the curators
27
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were unable to propagate the one P. mirabilis phage in their collection.
Effects of Phage Treatment on Homogeneous Biofilms
Biofilms of E. coli, P. aeruginosa, and P. mirabilis were first treated by each of the five phage
strains. As detailed within the Methods chapter, phage treatment was administered after the
biofilm was established. Thus, our evaluation is focused on the effectiveness of phage treatment
in reducing/eradicating biofilms. Furthermore, each of the bacterial strains used in this study
were the result of a selection experiment in which bacterial colonies that were efficient in their
ability to form biofilms were passaged serially (see Methods). Each treatment was conducted in
triplicate along with a control (no treatment). After treatment of each of the three homogeneous
biofilms, the efficacy of phage treatment was measured based on the biofilm’s absorbance and
individual species colony counts. While the former captures the presence of both viable and nonviable bacteria, the latter more closely represents the viable cells within the biofilm posttreatment. We also measured the mass of the biofilm before and after treatment, but found these
measurements to be unreliable as often biomass differences were not detected due to the lack of
precision available by our nanoscale. We thus do not include these measurements in our
discussions here. All boxplots shown represent untransformed data.
To ascertain the effectiveness of the five phages under investigation, we first examined
the treatment of monoculture biofilms of E. coli and P. aeruginosa. Statistically significant
effects were evaluated through the comparison of the biofilm density (absorbance or colony
counts) of untreated biofilms (control) and the treated biofilms. Figure 8 depicts boxplots of
absorbance and colony count data for E. coli and P. aeruginosa biofilms. Figures 8A and 8B
show the absorbance and E. coli colony counts, respectively, for the control lines (untreated) as
well as the treatments using Lust, Greedy, and Habibi. E. coli absorbance data was log
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3,8

transformed and an ANOVA was performed (F =9.792 P=0.0047). We found that treatments
with the phages Lust (P=0.02597) and Greedy (P=0.00427) were significantly different from the
control treatment when considering the absorbance (Figure 8A). However, treatment with Lust
was not found to be significant when considering the colony count data. As shown in Figure 8B,
the number of viable E. coli colonies (log-transformed) retrieved from the biofilm after treatment
with Lust was highly variable. Nevertheless, Greedy (P=0.00919) was significantly different
from control treatments for colony count data (F3,8=7.279 P=0.0113) (Figure 8B).
Figure 8C shows the measured absorbance from the untreated (control) P. aeruginosa
biofilms as well as those treated by the phages phiKZ, DMS3, and Habibi. Statistical methods
similar to that described for the absorbance data for the E. coli biofilms were conducted. No
significant differences between the control and the treatments were identified (Figure 8C). We
observed, however, that both phiKZ (P=0.00254) and DMS3 (P=0.04907) treatments resulted in
statistically significant differences from the untreated control biofilms (Figure 8D). This was
determined by performing box-cox normalization (lambda= -0.34) for the colony count data and
an ANOVA (F3,8=10.1 P=0.00427).
From the results of these assays, we found that Greedy and phiKZ are the most effective
at reducing biofilms of E. coli and P. aeruginosa, respectively (Figure 8). Quantifying the effects
of biofilm treatment via both absorbance and colony counts provides a means of distinguishing
between viable and inviable biofilms. For instance, the success of phiKZ treatment on the P.
aeruginosa biofilm was not significant for the absorbance data (Figure 8C); it was, however,
significant for the colony count data (Figure 8D). Thus, we believe that the colony count data
provides a more robust measure of the effect of phage treatment of biofilms.
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Figure 8. Effects of coliphage and P. aeruginosa phage treatments on homogenous E. coli and
P. aeruginosa biofilms measured by absorbance (panels A and C) and colony counts (panels B
and D). An asterisk denotes a statistically significant difference by Tukey’s multiple comparison
test where * indicates a P-value < 0.05 and ** denotes a P-value < 0.01.

To date, the method by which Greedy and Lust infect the E. coli C cell is unknown.
While a handful of coliphages exhibiting similar genomic sequences (Carstens et al. 2015, Doan
et al. 2015, Smith et al. 2015) have recently been published, they have not been characterized in
the laboratory; their growth parameters and mechanisms of infection are unknown. Within the
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Putonti lab both Greedy and Lust have been tested against several E. coli laboratory strains and
clinical E. coli isolates from the bladder, including strains from patients suffering from UTIs,
cystitis, and pyelonephritis as well as asymptomatic “healthy” individuals. While both Lust and
Greedy can lyse some E. coli strains from UTI patients, they were unable to lyse all UTIassociated E. coli strains tested. This is not surprising as the differences in genotype and
phenotype between the E. coli strains themselves are unknown and the same symptoms may
have different etiologies. Against this subset of bacteria tested, however, it is worth noting that
Greedy exhibited a broader host range than Lust as it was successful in infecting and lysing more
E. coli strains (in particular clinical strains) than Lust (Putonti et al., in preparation). The
observed difference between Greedy and Lust’s ability to reduce the E. coli biofilm is an
interesting area for further investigation.
In contrast to the coliphages, the Pseudomonas-infecting phages phiKZ and DMS3 have
been extensively characterized in the laboratory. In a study using the same strain of P.
aeruginosa used here, they found that phage KTN4 (a phiKZ-like-virus) disturbed biofilms and
reduced the production of pyocyanin and sideophores (Danis-Wlodarczyk et al. 2004).
Pyocyanin is a P. aeruginosa produced toxin that gives it its characteristic green color and plays
a role in biofilm formation (Lao et al. 2004). PhiKZ has also been used in studies that
aerosolized phage to test the feasibility of using inhalers to treat P. aeruginosa lung infections
(Golshahi et al. 2011, Matinkhoo et al. 2011). PhiKZ was found to have a dose dependent effect
on P. aeruginosa infections in mice lungs (Henry et al. 2013). Another study used phiKZ, along
with other Pseudomonas phages, to test the resilience of clinical isolates from chronic P.
aeruginosa infections; they found that these isolates had an increased susceptibility to phage
infection (Friman et al. 2013). DMS3 has been studied with particular relevance to its effect on
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biofilms. It has been shown to reduce swarming motility in P. aeruginosa PA14 via the CRISPRCas system (Zegans et al. 2009, Chung et al. 2012). Furthermore, DMS3 lysogeny blocks
biofilm formation in P. aeruginosa PA14 with a 50% reduction of attachment in the first 30 mins
(Zegans et al. 2009). Given this prior work, it is thus not surprising that DMS3 was effective in
disrupting the viability of the P. aeruginosa biofilm (Figure 8D).
Phage treatments for biofilms of non-host species included the treatment of P. mirabilis
biofilms with all five phages, coliphage treatment of P. aeruginosa biofilms, and Pseudomonas
phage treatment of E. coli biofilms. Figure 9 shows the absorbance measurements of these
treatments while Figure 10 shows the colony counts for these treatments. Looking first at the
absorbance results, no statistically significant effect in the P. mirabilis biofilms was observed
(Figure 9A). While visually it appears that the Habibi treatment did lead to a decrease in P.
mirabilis biofilms (per absorbance measurements), this was not statistically significant
(P=0.281). In contrast, treatment of E. coli biofilms by both Pseudomonas-infecting phages had
an effect (Figure 9B). E. coli absorbance data was normalized (box-cox transformation,
lambda=-0.94) and an ANOVA was performed (F2,6=45.63 P=0.000235). The effect of phiKZ
(relative to the untreated control biofilms) was statistically significant (P<0.001) as was the
effect of DMS3 (P<0.001). No statistically significant effect was identified for coliphage
treatments of P. aeruginosa biofilms (Figure 9C).
To ascertain if the treatments had an effect on the viable bacterial community of the
biofilm, colony count data was considered (Figure 10). Paralleling that observed for the
absorbance data (Figure 9), no significant effect was observed for the P. mirabilis (Figure 10A)
and P. aeruginosa (Figure 10C) biofilms. However, the Pseudomonas phages phiKZ and DMS3
treatment of the E. coli biofilms had an effect on the biofilm community; E. coli colony count
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data was normalized (box-cox transformation, lambda= -0.69) and an ANOVA was performed
(F2,6=20.64 P=0.00204). PhiKZ (P=0.00546) and Greedy (0.00245) were found to be
significantly different from the control treatment.

Figure 9. Effects on the biofilms, as measured by absorbance, for phage treatments of non-host
phage species. (A) Treatments for all five phages on P. mirabilis biofilms. (B) Treatments for
phiKZ and DMS3 phages on E. coli biofilms. (C) Treatments of coliphages Lust and Greedy on
P. aeruginosa biofilms. An asterisk denotes a statistically significant difference by Tukey’s
multiple comparison test where *** indicates a P-value < 0.001.

Figure 10. Effects on the biofilms, as measured by colony counts, for phage treatments of nonhost phage species. (A) Treatments for all five phages on P. mirabilis biofilms. (B) Treatments
for phiKZ and DMS3 phages on E. coli biofilms. (C) Treatments of coliphages Lust and Greedy
on P. aeruginosa biofilms. An asterisk denotes a statistically significant difference by Tukey’s
multiple comparison test where ** indicates a P-value < 0.01.

It is interesting that P. aeruginosa phages had a significant effect on E. coli biofilms
despite their inability to lyse E. coli. Lysis is not the only way that a phage can inhibit bacterial
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growth. For example, as mentioned previously, when DMS3 switches to lysogeny it inhibits P.
aeruginosa biofilm formation (Zegans et al. 2009). Adsorption induced lysis as a result of high
concentrations of phage is another possibility (Abdeon 2011, Turner and Chao 1998).
Additionally, phages may produce toxins or enzymes that inhibit bacterial growth, or perhaps the
phages are attaching to the cell wall but are unable to degrade and enter the cell. There is still
much to learn about bacteriophages and the ways they interact with bacteria.
Effects of Phage Treatment on Heterogenous Biofilms
In addition to the phage treatments applied to homogenous biofilms of E. coli, P. aeruginosa,
and P. mirabilis, complex communities of biofilms were created. Biofilms consisting of each
pair as well as all three of these CAUTIs-associated bacteria were established in the same
manner as the homogeneous biofilms (see Methods). Thus, four heterogeneous biofilms were
considered in this study: E. coli and P. aeruginosa (EP), E. coli and P. mirabilis (EM), P.
aeruginosa and P. mirabilis (PM), and all three bacteria (EPM). Again, each treatment was
conducted in triplicate in addition to a control (no treatment).
While absorbance measures revealed that Lust and Greedy phage treatments had a
statistically significant effect on homogeneous E. coli biofilms (Figure 8A), the same cannot be
said for the heterogeneous biofilms. As shown in Figure 11, no statistically significant effect was
detected by means of absorbance for any of the heterogenous biofilms treated with any of the
phage. Total colony count data, however, show a different trend; several of the treatments of the
PM (Figure 12C) and EPM (Figure 12D) biofilms reveal significant effects. The total colony
count represents the number of viable bacteria, regardless of species, in the heterogenous
biofilm. The PM total colony count data was normalized (log-transformation) and an ANOVA
was performed (F5,12=3.466 P=0.0361). A significant effect to the biofilm was only found when
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considering the untreated (control) and Lust treatments (P=0.0294) (Figure 12C). The EPM total
colony count data was also log-transformed and an ANOVA was performed (F5,12=5.096
P=0.00977). As Figure 12D shows, a significant difference was found between the untreated
control and four of the treatment regimens: Greedy (P=0.03056), Lust (P=0.00998), phiKZ
(P=0.02728), and Habibi (P=0.01750).

Figure 11. Effects of phage treatments, quantified by absorbance, on heterogenous biofilms of:
(A) E. coli and P. aeruginosa, (B) E. coli and P. mirabilis, (C) P. aeruginosa and P. mirabilis,
and (D) E. coli, P. aeruginosa, and P. mirabilis.
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Figure 12. Effects of phage treatments, quantified by total colony count, on heterogenous
biofilms of: (A) E. coli and P. aeruginosa, (B) E. coli and P. mirabilis, (C) P. aeruginosa and P.
mirabilis, and (D) E. coli, P. aeruginosa, and P. mirabilis. An asterisk denotes a statistically
significant difference by Tukey’s multiple comparison test where * indicates a P-value < 0.05
and ** indicates a P-value < 0.01.

While Figure 12 captures the overall viability of the biofilm community, we were
interested in investigating specifically how each of the phage treatments impacted the individual
constituents of the complex community. Thus, for each plate, individual colonies were identified
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by species based upon their morphological features. Figures 13 and 14 present a breakdown of
the colony counts by species for the two-species biofilms and three-species biofilms,
respectively.
Where we saw four of the five phage treatments were significantly different from the
control in EPM biofilms in regards to total colony counts (Figure 12), we only see a significant
effect in P. aeruginosa individual colony counts (Figure 14). P. aeruginosa colony counts were
normalized (log-transformation) and ANOVA was performed (F5,12=4.403 P=0.0165). PhiKZ
was found to have a significant effect on EPM biofilms (P=0.0397). Furthermore, for the twospecies biofilms we see significant effects with respect to P. aeruginosa colony counts in PM
biofilms (Figure 13F). After log-transformation, an ANOVA was performed (F5,12=5.311
P=0.00838), and effects were found for both phiKZ (P=0.0124) and DMS3 (P=0.0397). We also
identified a significant difference between treatments for E. coli colony counts in the EM
biofilms when a Kruskal-Wallis was performed (χ2=15.739, df=5, P=0.007631). P. mirabilis
colony counts (log-transformed) also showed a significant ANOVA in EM biofilms (F5,12=3.548
P=0.0336); there was a significant difference between Greedy and Lust treatments (P=0.0403).
For E. coli colony counts treated with Greedy, no colonies were observed at the dilutions plated.
To perform a box-cox transformation (lambda=0.23) 1.0e+04 was used in place of zero, this
number was chosen because it is the dilution E. coli colonies plated at when homogenous E. coli
biofilms were treated with Greedy. Then an ANOVA was performed (F5,12=4.146 P=0.0203);
Greedy (P=0.0213) and Habibi (P=0.0250) were significantly different from control treatments.
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Figure 13. The effects of phage treatments, quantified by species colony counts, on
heterogenous biofilms. (A) P. aeruginosa colony counts in E. coli and P. aeruginosa biofilms,
(B) P. mirabilis colony counts in E. coli and P. mirabilis biofilms, (C) P. mirabilis colony counts
in P. aeruginosa and P. mirabilis biofilms, (D) E. coli colony counts in E. coli and P. aeruginosa
biofilms, (E) E. coli colony counts in E. coli and P. mirabilis biofilms, and (F) P. aeruginosa
colony counts in P. aeruginosa and P. mirabilis biofilms. An asterisk denotes a statistically
significant difference by Tukey’s multiple comparison test where * indicates p<0.05.
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Figure 14. The effect of phage treatments, quantified by species colony counts, on heterogenous
E. coli, P. aeruginosa, and P. mirabilis biofilms. (A) E. coli colony counts, (B) P. aeruginosa
colony counts, and (C) P. mirabilis colony counts.

Biofilm Response to Treatment with Broad Host Range Phage Habibi
Given Habibi’s ability to infect both E. coli and P. aeruginosa, we originally hypothesized that it
would be an effective phage treatment for both homogenous biofilms of E. coli and P.
aeruginosa as well as a heterogeneous biofilm containing the two bacteria species. While
presented in prior figures, the direct comparisons for no treatment and Habibi treatments are
shown here. While absorbance data indicated no significant effects (Figure 15), a statistically
significant effect was detected using colony counts data for the P. aeruginosa biofilms (Figure
16C) as well as for the E. coli population of the EP biofilms (Figure 16B).
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Figure 15. Effects of Habibi phage treatments on (A) E. coli, (B) P. aeruginosa, and (C) E. coli
and P. aeruginosa biofilms, assessed via absorbance.
When considering the viable bacteria within the heterogeneous EP biofilm, we
anticipated that Habibi treatment would have a greater effect on Pseudomonas as we have
previously observed a higher plating efficiency of Habibi on P. aeruginosa relative to E. coli C.
The homogenous P. aeruginosa biofilms supported this conjecture (Figure 16C). P. aeruginosa
colony count data for P. aeruginosa biofilms was normalized (box-cox transformation, lambda=
-0.38) and an independent sample t-test was performed (t=4.4422, df=2.4384, p=0.03235).
Despite this observation for the homogenous biofilm, the P. aeruginosa colony count from the
EP biofilm Habibi treatments did not show a decrease in the number of viable cells. From a
purely visual inspection of the log-transformed data in Figure 16D, Habibi had a varied effect on
the P. aeruginosa cells; one of the replicates had 10x more P. aeruginosa colonies than the other
two replicates. A statistically significant effect was observed for the E. coli colonies within these
same treatments of the heterogenous EP biofilms. E. coli colony counts for EP biofilms were
normalized (log-transformation) and an independent samples t-test was performed (t=4.508,
df=3.8486, P=0.01175). E. coli densities between the three replicates were consistent.
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Figure 16. Effects of Habibi phage treatments, quantified by colony counts, on (A) E. coli in
homogeneous E. coli biofilms, (B) the E. coli population in EP biofilms, (C) P. aeruginosa in
homogeneous P. aeruginosa biofilms, and (D) the P. aeruginosa population in EP biofilms. An
asterisk denotes a statistically significant difference by Tukey’s multiple comparison test where *
indicates a P-value < 0.05.

Biofilm Response to Treatment with Phage Cocktails
Due to the fact that the broad host range phage of Habibi was not effective in reducing both the
P. aeruginosa and E. coli populations of the EP biofilm, we decided to try and target the two
bacteria by means of a phage cocktail. From the individual phage treatments of both
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homogeneous and heterogeneous biofilms, the coliphage Greedy and the Pseudomonas phage
phiKZ were selected for the phage cocktail. As with Habibi, we assessed the differences between
Greedy, phiKZ, and Greedy+phiKZ (henceforth denoted as “G+phi”) treatments by both the
recorded absorbance (Figure 17) and single species colony count data (Figure 18).
The E. coli biofilm absorbance data was normalized using the box-cox transformation
(lambda=-0.94). As shown in Figure 17A, we see that every phage treatment was significantly
different from the untreated control (ANOVA, F3,8=18.2 P=0.000622). Tukey’s multiple
comparison test was performed finding statistical significance between: untreated and G+Phi
treatment (P= 0.00575), untreated and Greedy (P= <0.001), and untreated and phiZK
(P=0.00434). The absorbance data collected for the P. aeruginosa biofilms was log transformed
and an ANOVA was performed. In contrast to the results observed for the E. coli biofilms, none
of the phage treatments had a significant effect on the P. aeruginosa biofilm per the absorbance
measure (Figure 17B). In the heterogenous EP biofilms (Figure 17C), only the G+Phi treatment
was statistically significant in relation to the untreated biofilms (ANOVA, F3,8=17.39
P=0.00726). Tukey’s multiple comparison test between untreated and G+Phi treatment resulted
in P= 0.00285.
Statistically significant effects due to phage treatment of the E. coli biofilms were also
observed when considering colony counts. In Figures 18A and 18B we see a significant effect in
the E. coli populations after treatment of both the E. coli and EP biofilms. Colony counts from
the E. coli biofilms were log-transformed and an ANOVA was performed (F3,8=33.74 P=6.87e05). Tukey’s multiple comparison test was performed finding statistical significance between: no
treatment and G+Phi treatment (P= <0.001) and no treatment and Greedy (P= <0.001). Phage
treatment of the E.coli population in EP biofilms was also significant (box-cox transformed,
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lambda=0.07; ANOVA, F =103.4 P= 9.74e-07). Tukey’s multiple comparison test was next
3,8

performed identifying statistical significance between the control (no treatment) and the G+Phi
treatment (P<0.001) and between the control (no treatment) and the Greedy treatment (P<0.001).

Figure 17. Effect of phage treatment of Greedy, phiKZ, and Greedy+phiKZ cocktail on (A) E.
coli, (B) P. aeruginosa, and (C) EP biofilms based upon absorbance (660 nm). An asterisk
denotes a statistically significant difference by Tukey’s multiple comparison test where ***
indicates a P-value < 0.001 and ** indicates a P-value < 0.01.

While the absorbance assays indicated no significant effect in the concentration of P.
aeruginosa bacterial cells (or cell matter) within the homogenous biofilm, colony counts tell a
different story. In Figures 18C and 18D, a significant effect is observed for phage treatment of
both the P. aeruginosa and EP biofilms. P. aeruginosa biofilms’ (log transformed) ANOVA was
significant (F3,8=7.405 P= 0.0107); Tukey’s multiple comparison test between no treatment and
phiKZ treatment is statistically significant (P= 0.0166). Similar statistics were performed for the
P. aeruginosa colony count data from the EP biofilms (log-transformed ANOVA, F3,8=18.22 P=
0.000619; Tukey’s multiple comparison test between no treatment and G+Phi treatment (P=
0.00908).
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Figure 18. Effects of phage treatments of Greedy, phiKZ, and Greedy+phiKZ (G+Phi) cocktail
on (A) E. coli in homogeneous E. coli biofilms, (B) the E. coli population in EP biofilms, (C) P.
aeruginosa in homogeneous P. aeruginosa biofilms, and (D) the P. aeruginosa population in EP
biofilms. An asterisk denotes a statistically significant difference by Tukey’s multiple
comparison test where * indicates a P-value < 0.05, ** a P-value< 0.01, and *** a P-value<
0.001.
From the results of the cocktail treatments, in particular the colony counts presented in
Figure 18, three observations can be made. First, Greedy was highly efficient in reducing the
number of viable cells within the homogeneous E. coli biofilm. This efficiency in killing E. coli
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cells was also apparent when it was used to treat the EP biofilm (Figure 18B). While it had no
substantial effect on the P. aeruginosa biofilm (Figure 18C) it produced a dramatic effect on the
P. aeruginosa population within the EP biofilm. While Greedy is highly unlikely to have
“promoted” P. aeruginosa growth, this is likely a residual effect of its efficacy in lysing E. coli
cells within the biofilm. Thus, we speculate that the decline in E. coli within the treated EP
biofilms increased the resources available for P. aeruginosa growth. Based on P. aeruginosa’s
ability to persist and even proliferate in the absence of E. coli within these treated biofilms, we
hypothesize that the two bacteria species are not as cooperative as has been observed within
other multispecies biofilms (Nozhevnikova et al. 2015) and may even be antagonistic, fighting
for resources. Secondly, phiKZ was only found to produce a significant effect on the
homogeneous P. aeruginosa population. The cocktail, however, was not found to be significant
in the P. aeruginosa biofilm, perhaps because of the reduced titer of phiKZ. Lastly, the phage
cocktail was effective on both bacteria species within the heterogenous EP biofilm.
Planktonic Fraction
The planktonic fraction, or the free-living independent bacteria outside of the biofilm, have
substantially different metabolic characteristics (Davey and O’Toole 2000). They are,
nevertheless, a vital part of the ecosystem representative of bacterium which can be recruited and
integrated during biofilm development or dispersed members of a biofilm (Figure 1). Thus, in
addition to examination of the biofilm bacterial communities, the planktonic fraction was also
evaluated post-treatment. The same metrics were used to evaluate the planktonic fraction as were
used for evaluation of the biofilms. The absorbance data and colony counts from the planktonic
fraction of the homogeneous biofilm treatments and the heterogeneous biofilm treatments are
shown in Figures 19 and 20, respectively.
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For the E. coli biofilm’s planktonic fraction, we detected a significant difference in
absorbance between the treatments (Figure 19A); a Kruskal-Wallis test was found to be
significant (χ2 = 14.099, df = 5, P= 0.01499). Similarly, the five treatments had different effects
on the bacterial community within the planktonic fraction of the P. aeruginosa biofilms (Figure
19B). The Kruskal-Wallace χ2 statistic = 14.17, df = 5, p-value = 0.01457. As expected, no
significant effect was observed for the P. mirabilis community.
In addition to measuring the absorbance, aliquots from the planktonic fraction were
plated and colonies counted (see Methods). For the E. coli biofilm treatments, an ANOVA was
performed (F5,12=18.4 p=2.96e-05). As Figure 19D shows, only the Greedy treatment was found
to have a statistically significant relative to the untreated control (P=0.00603). To assess the
putative effects on the P. aeruginosa population within the planktonic fraction, the colony count
data was normalized (log-transformation) and an ANOVA was performed (F5,12= 20.41 p=3.15e05). PhiKZ (P=0.01726), DMS3 (P<0.001) and Habibi (P=0.00386) were found to have a
significant effect relative to the untreated (control) biofilm planktonic fraction (Figure 19E).
Again as expected, no significant effect was observed for the planktonic fraction’s P. mirabilis
community.

47

Figure 19. Effects of phage treatments on the planktonic fraction of homogenous E. coli, P.
aeruginosa, and P. mirabilis biofilms measured by absorbance (panels A through C) and colony
counts (panels B through D). An asterisk denotes a statistically significant difference by Tukey’s
multiple comparison test where * indicates a P-value < 0.05, ** denotes a P-value < 0.01, and
*** indicates a P-value < 0.001.
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Figure 20. Effects of phage treatments on the planktonic fraction of heterogeneous biofilms
measured by absorbance (panels A through D) and colony counts (panels F through I).

Evaluation of the effects of phage treatment within the planktonic fraction was next
evaluated for the heterogenous biofilms, again using absorbance (Figure 20, panels A through D)
and total colony counts (Figure 20, panels F through I). From these total colony counts, the only
statistically significant result was from an ANOVA of the EPM treatments (F5,12=3.629
p=0.0313). given this observed difference, Tukey’s multiple comparison test was performed.
While no statistically significant difference between the control and individual treatments was
found, the Lust treatment was significantly different from Greedy treatment (P=0.018); this
difference between Lust and Greedy was the reason the ANOVA produced a significant result.
To ascertain if the changes in total colony counts were due to an individual species, we
next investigated these colony counts by species (Table 4). The most intriguing result found was
the increase in P. mirabilis in the EM and PM biofilm planktonic fraction in response to
treatment by Greedy. While one could hypothesize that this increase in the EM was due to the
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effectiveness of Greedy in lysing E. coli cells, and thus reducing resource constraints for P.
mirabilis, it is confounding to see a similar – and more profound – effect in the PM biofilm’s
planktonic fraction. This warrants further investigation of P. mirabilis and P. aeruginosa
interactions within liquid culture.
Treatment
None
Lust
Greedy
PhiKZ
DMS3
Habibi
Biofilm Bacteria
EP
E. coli
6.73E+07 7.07E+07
N/A 6.40E+07 8.03E+07 2.27E+07
P. aeruginosa 3.17E+07 2.23E+07 1.42E+08
N/A
N/A 1.33E+06
EM
E. coli
2.00E+06
N/A
N/A 2.50E+07 0.00E+00 0.00E+00
P. mirabilis
1.72E+08 1.15E+08 6.08E+08 1.06E+08 1.27E+08 1.53E+08
PM
P. aeruginosa 9.00E+06 6.67E+06 9.00E+06
N/A
N/A 6.67E+05
P. mirabilis
2.93E+08 1.50E+08 1.51E+09 2.25E+08 2.39E+08 1.59E+08
EPM
E. coli
1.10E+07
N/A 6.67E+05 7.00E+06 2.60E+07 1.67E+06
P. aeruginosa 7.00E+06 4.00E+06 2.33E+06
N/A 3.33E+05 1.33E+06
P. mirabilis
1.19E+08 9.87E+07 1.82E+08 1.20E+08 1.21E+08 1.48E+08
Table 4. Colony counts within the planktonic fraction for heterogeneous biofilm treatments by
species. N/A means that no colonies grew at the dilutions plated.

Host Resistance to Phage Infection
Because no single phage or the phage cocktail completely destroyed the biofilms, although
Greedy was close to successful for the E. coli biofilm treatments (Figure 8A and B), we next
determined if the resilience of the biofilm was the result of bacterial resistance to the phage.
Randomly selected bacterial colonies were thus selected and challenged by the phage used in the
treatment (see Methods Figure 7). As expected, P. mirabilis remained resistant to all five phages,
regardless if it was a homogeneous or heterogenous biofilm. Figure 21 provides a graphical
representation of the resistance observed for E. coli colonies from the five treatment regimens of
E. coli biofilms (Figure 21A) and the planktonic fraction (Figure 21C). Figure 21 panel B and D
show the results for the P. aeruginosa colonies in the biofilm and planktonic fraction,
respectively.
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Figure 21. Bacterial resistance for bacterial isolates from within homogeneous biofilms. NT
signifies isolates collected from the untreated (control) biofilms, and T represents those collected
for the phage treatment samples. Panels A and B present the percentage of colonies resistant,
partially resistant, or phage-sensitive from the E. coli and P. aeruginosa biofilms, respectively.
Panels C and D include the percentages for colonies from the planktonic fraction of E. coli and
P. aeruginosa biofilms, respectively.

Colonies from both the untreated (NT) and treated (T) samples are included in the graph.
The NT bar charts represent the likelihood of resistance occurring a priori. It is important to note
that phage sensitivity is not an absolute in, for example, E. coli. Colonies resistant to Greedy
were observed both in the biofilm as well as the planktonic fraction (21A and C). Also of note is
the occurrence of E. coli colonies which were sensitive to either phiKZ or DMS3 which is not
believed to be infective of bacteria outside of the Pseudomonas genus. While these innate
resistances and sensitivities may have arisen as a result of the selection experiment deriving the
strains used for our experiment, the fact that they are seen in such small numbers suggests this is
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not the case. Similar unexpected results were observed for the NT colonies tested from the P.
aeruginosa experiments. In fact, the majority of the biofilm colonies were resistant or partially
resistant to phiKZ and DMS3 and all of the biofilm colonies were resistant or partially resistant
to Habibi. This may be a contributing factor to the minimal effect observed for the Habibi
treatments (Figures 15 and 16). Furthermore, the ability for a phage to infect and successfully
lyse a bacteria cell is traditionally assayed either via liquid culture or on a plate, as we have done
here. The ability for a phage to lyse within the unique spatial organization of a biofilm is
unknown.
For the four complex biofilms, resistance was tested for colonies of each (in the case of
EP, EM, and PM) or all three (EPM) bacterial species. In complex biofilms with E. coli present
treatment with Greedy and Lust resulted in few if any E. coli colonies growing at the dilutions
plated. As such, we were unable to test for host resistance. Similarly, in multispecies biofilms
with P. aeruginosa present treatment with PhiKZ, DMS3 and Habibi resulted in few if any P.
aeruginosa colonies growing at the dilutions plated for the planktonic fraction. Thus, only P.
aeruginosa from the biofilm was able to be tested for host resistance. Partial susceptibility to
phage infection was more common in P. aeruginosa than E. coli. Table 5 summarizes the results
of these resistance assays for the heterogenous biofilms for colonies isolated from the biofilms
themselves, while Table 6 summarizes the results from the planktonic fraction. The results in
Table 6 show an intriguing trend in which the P. aeruginosa colonies from the phage treatments
were more sensitive than the untreated cultures. This contradicts our assumptions that resistance
arises in response to phage predation and thus warrants further investigation. The results of the
resistance assays for the G-phi treatments are shown in Figure 22.
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NT
T

P. aeruginosa

T

E. coli

NT

Phage
Category Lust Greedy phiKZ DMS3 Habibi
0
0
24
26
0
Resistant
0
0
3
0
7
Partial
27
27
0
1
20
Sensitive
0
0
25
27
10
Resistant
0
0
1
0
8
Partial
9
2
0
0
3
Sensitive
N/A
18
25
1
0
6
27
27
0
0
0
Resistant
0
0
24
26
25
Partial
0
0
3
1
2
Sensitive
27
27
3
1
0
Resistant
0
0
19
15
22
Partial
0
0
1
11
5
Sensitive
N/A
0
0
4
0
0
Table 5. Bacterial resistance for isolates from within heterogeneous biofilms.

NT
T

P. aeruginosa

T

E. coli

NT

Phage
Lust
Greedy
phiKZ
DMS3 Habibi
Category
Resistant
0
0
26
25
0
Partial
0
0
1
2
11
Sensitive
27
27
0
0
16
Resistant
0
0
22
27
20
Partial
0
0
5
0
2
Sensitive
9
1
0
0
0
N/A
18
26
0
0
5
Resistant
27
27
3
3
3
Partial
0
0
20
20
22
Sensitive
0
0
4
4
2
27
27
0
0
0
Resistant
0
0
0
1
11
Partial
0
0
0
0
1
Sensitive
N/A
0
0
27
26
14
Table 6. Bacterial resistance for isolates from within planktonic fraction of heterogeneous
biofilms.
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Figure 22. Bacterial resistance for isolates treated with phage cocktail within the (A) biofilm and
(B) planktonic fraction. Areas denoted by the hashed bar indicate samples for which the
effectiveness of the phage treatment resulted in no retrievable colonies of the particular bacteria.

Phenotypic Changes in Bacterial Species
In addition to determining the relative number of viable colonies for each species present
in a biofilm, plating also allowed us to observe multiple morphological changes in colony
phenotype. In six of the samples containing P. aeruginosa, a red colony morphology was
observed (Figure 23). These samples included isolates from both the biofilm and planktonic
fraction of the same replicate of the untreated Pseudomonas control. Two of the replicates from
the Pseudomonas biofilm treated with phiKZ also contained a “Red Pseudomonas.” Other
samples include one replicate of the untreated PM planktonic fraction, one replicate of
Pseudomonas treated with Habibi, and two replicates of Pseudomonas treated with G+phi. These
colonies appeared as normal, however once streaked on an LB plate, a red pigment was diffused
through the agar. Pseudomonad species are known to diffuse colored pigments throughout their
media. The P. aeruginosa 1C strain, used routinely in our lab, typically produces pyocyanin
which is responsible for its characteristic green color and pyomelanin (brown) when the culture
is old (Ogunnariwo and Hamilton-Miller 1974). This was the first time we observed the redbrown pigment pyorubin in our laboratory strain.
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Figure 23. P. aeruginosa red colony phenotype.

P. aeruginosa biofilms treated with DMS3, phiKZ, or Habibi resulted in numerous
colonies presenting a morphology quite different from those observed in untreated biofilms.
Altered phenotypes consisted of P. aeruginosa colonies which maintained their color but were
usually smaller in size and appeared as though pieces of their colonies were missing. These
colonies had jagged edges rather than their normal circular shape. Restreaking these colonies
resulted in their return to normal colony morphology; thus, the change in morphology was not
likely due to a genetic source as it was not inheritable. These phenotypes had higher frequencies
in the planktonic fraction than the biofilm portion of the samples. This is consistent with
previous findings that show P. aeruginosa phages are effective at reducing additional biofilm
formation by preventing the aggregation of dispersed members of the biofilm in the planktonic
fraction (Darch et al. 2017).
Novel colony morphologies were also observed in E. coli biofilms treated with Lust and
Greedy. E. coli colonies were smaller and jagged-edged in contrast to smooth-edged. Despite the
fact that these two phages were isolated in our lab (Malki et al. 2015) and have been plated with
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E. coli C numerous times prior, this was the first time this E. coli C morphology has been
observed. As a precaution, the E. coli C biofilm treatment with Greedy was repeated, again in
triplicate, and produced similar E. coli C cell morphologies. Colonies from these plates were
selected and restreaked producing a second generation of aberrant colonies. Furthermore, in
contrast with the E. coli C lab strain in our collection (and the ancestor of the inoculant of the
biofilms), the restreaked E. coli grew slower. It is important to note that not all colonies on a
plate showed these altered morphologies, and similar to phenotypic responses observed in P.
aeruginosa, the altered colonies were more frequently observed in the planktonic fraction rather
than in the biofilm community. This observation is consistent with the protective nature of
biofilms.
An additional change to colony morphology was observed in biofilms containing both E.
coli and P. aeruginosa treated with DMS3. Here a few colonies from the biofilm portion of the
samples appeared to have swarming abilities. While frequently observed for P. aeruginosa and
P. mirabilis colonies from all biofilms, E. coli swarming colonies were only observed in EPD
biofilms. Perhaps this morphology was a result of horizontal gene transfer which occurs in
higher rates in biofilms (see review Madsen et al. 2012).
Phage Populations within Treatments
While spotting phage to test host range and isolate individual plaques for identification, the last
dilution at which plaquing occurred was recorded, though specific titers were not. From this we
noticed a few interesting trends. As expected the concentration of phage was higher in the
planktonic fraction than the biofilm fraction of samples for every phage. Additionally, all phages
except Habibi had their lowest concentrations in EPM biofilms, for Habibi it was E. coli
biofilms. Another interesting observation about Habibi was that it had a higher concentration in
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EM biofilms than E. coli biofilms despite no observed plaques on P. mirabilis lawns. Something
similar occurred with phage DMS3 which had equal concentration of phage in P. aeruginosa and
EP biofilms despite a lack of plaques on E. coli lawns. This is probably because when treated
with DMS3 EP biofilms did better than P. aeruginosa biofilms. Furthermore, this is intriguing
when you consider the fact that while DMS3 and Habibi had no plaques on E. coli or P. mirabilis
lawns; after treatment of EM, PM, and EPM biofilms, both phages resulted in visibly less turbid
lawns when spotted on E. coli and P. mirabilis. This was not observed in E. coli or P. mirabilis
biofilms treated with the phages individually. Lust had its highest concentrations in EP and EM
biofilms. Greedy did the best in E. coli biofilms. PhiKZ and DMS3 were most successful in P.
aeruginosa biofilms. Habibi saw its highest concentrations in EP biofilms, which was expected
considering its ability to infect both members of the biofilm.
Pseudomonas aeruginosa Prophage
Despite previously unsuccessful attempts from members of our lab trying to manipulate P.
aeruginosa to release its prophage, throughout this experiment we observed the prophage
multiple times. A prophage is a bacteriophage genome inserted into the bacterial chromosome or
plasmid that is only released upon activation by things such as host stress (Figure 24). It was
released in untreated P. aeruginosa biofilms and also in untreated biofilms composed of both P.
aeruginosa and E. coli. Interestingly, it was not released in untreated biofilms containing P.
mirabilis (PM or EPM biofilms). Additionally, the prophage was not released in P. aeruginosa
biofilms treated with either Lust or Greedy. However, in EPM biofilms treated with Lust, one
replicate showed the appearance of the prophage. In EPM biofilms treated with Greedy, the
prophage appeared in all three replicates. Plaque morphology was observed as pin point plaques
with crisp edges and a very clear center. Upon spotting the prophage on both E. coli and P.
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mirabilis lawns, no lysis was observed. In a few instances, spotting the prophage on P.
aeruginosa resulted in plaquing that was not confined to the spots but rather was observed
throughout the plate.

Figure 24. Bacteriophage life cycle.
Prophage concentrations ranged from 102-108 with planktonic concentrations about 10fold higher than their biofilm counterparts. In all cases except P. aeruginosa untreated biofilms,
the concentration of prophage released was higher in replicates with higher absorbance values
and thus thicker biofilms. Combined, these observations suggest that there is a relationship
between prophage release and increased biofilm production in our strain of P. aeruginosa. This
hypothesis is supported by other studies observing a similar correlation. For instance,
Streptococcus pneumoniae biofilm production is aided by prophage mediated lysis which
releases DNA into the environment which aides in biofilm formation as extracellular DNA is an
important component of the matrix (Carrolo et al. 2010). Enhanced biofilm formation due to
phage mediated release of DNA was also observed in Shewanella oneidensis (Gödeke, et al.
2011), and E. faecalis (Rossman et al. 2015).

CHAPTER FOUR
CONCLUSION
Our examination of the literature found phage to be more effective at biofilm inhibition than
eradication, as such we did not initially expect any of our phages to substantially reduce biofilm
density. In this aspect the effects of Greedy treatments exceeded our expectations. We saw that
Greedy produced statistically significant reductions in homogeneous biofilms, when compared to
the control, quantified by both absorbance and colony counts. We also found Greedy’s effect
spread into the E. coli colony counts in the planktonic fraction. Furthermore, Greedy had a
significant effect in EPM biofilms, with regards to the total colony count data, and in EP biofilms
(for E. coli colony counts). When combined with phiKZ, the cocktail treatment of EP biofilms
resulted in a significant effect, per the absorbance data. This is particularly intriguing as
absorbance data represents both the viable and non-viable portions of the biofilm, thus giving a
more accurate representation of biofilm density. Greedy treatments also produced altered colony
morphologies; bacterial colonies were both smaller and had a slower growth rate relative to their
ancestor. As on-going research in our lab characterizing Greedy has found, it is able to infect and
lyse several clinical E. coli strains isolated from patients presenting with UTIs. For these reasons,
we believe that Greedy is a strong candidate for future research in biofilm reduction, and more so
in phage treated catheter studies for biofilm prevention. Follow up studies, investigating the
effectiveness of Greedy in preventing biofilm formation as well as the efficacy of Greedy
treatments over time, would provide greater insight into its potential for phage therapy.
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This study was the first, to our knowledge, to examine three species biofilms composed
of CAUTI-associated bacteria. Despite catheter biofilms, and biofilms in general, being
composed of multiple species of bacteria, much of the current research focuses on homogenous
biofilms. Prior studies have found catheter biofilms containing up to five different bacterial taxa
(Saint and Chenoweth 2003). As we have shown here, an effect on a single species biofilm is not
necessarily reflected in more complex, heterogeneous biofilms. For example, while Lust had a
significant effect on E. coli biofilm absorbance, it loses that effect in EP, EM and EPM biofilm
absorbance. We did not observe any significant effects of any phage treatment on heterogenous
biofilms quantified by absorbance. Furthermore, we saw no significant effects, based on total
colony counts, in EP biofilms despite all five of our phages infecting both species within it. We
urge future studies to consider the more naturally occurring complex, multispecies biofilms.
Among the many interesting results of this study, perhaps the most alarming observation
was the effect of phage treatment on non-host bacteria. While P. mirabilis was not significantly
affected by any of the phage treatments, we did see an inflation of P. mirabilis colonies counts in
the planktonic fraction of EM and PM biofilms in response to treatment with Greedy.
Furthermore, P. aeruginosa phage treatments with phiKZ and DMS3 also had a significant effect
on E. coli biofilms; within the literature, neither phage has been identified as capable of lysing E.
coli cells. Additionally, we showed that phages Lust, Greedy, phiKZ, and DMS3 can reduce E.
coli C populations in the multispecies EPM biofilm community. Our study clearly shows that
phage treatment of heterogenous biofilms does not only affect the species in which it is capable
of lysing. This provides direct evidence that phages can inhibit bacterial growth or induce lysis
without successful infection.

60
Future work in phage remediation should consider the entire microbial population at
stake rather than focusing solely on the most problematic bacterial species. This is especially true
for phage therapy of human infections, as maintaining a “normal” microflora is critical for
human health. Phage treatment has the potential to disrupt beneficial microbes that could lead to
unintended consequences. Nevertheless, phage therapy has significant potential to improve
human health and combat infections including CAUTIs, particularly given the increase in
antibiotic-resistant bacteria.
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